Correlation Between Acrivon Therapeutics, and Protagenic Therapeutics

Can any of the company-specific risk be diversified away by investing in both Acrivon Therapeutics, and Protagenic Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Acrivon Therapeutics, and Protagenic Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Acrivon Therapeutics, Common and Protagenic Therapeutics, you can compare the effects of market volatilities on Acrivon Therapeutics, and Protagenic Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Acrivon Therapeutics, with a short position of Protagenic Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Acrivon Therapeutics, and Protagenic Therapeutics.

Diversification Opportunities for Acrivon Therapeutics, and Protagenic Therapeutics

0.32

Correlation Coefficient

Acrivon Therapeutics,  Protagenic Therapeutics

Weak diversification

The 3 months correlation between Acrivon and Protagenic is 0.32. Overlapping area represents the amount of risk that can be diversified away by holding Acrivon Therapeutics, Common and Protagenic Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Protagenic Therapeutics and Acrivon Therapeutics, is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Acrivon Therapeutics, Common are associated (or correlated) with Protagenic Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Protagenic Therapeutics has no effect on the direction of Acrivon Therapeutics, i.e., Acrivon Therapeutics, and Protagenic Therapeutics go up and down completely randomly.

Pair Corralation between Acrivon Therapeutics, and Protagenic Therapeutics

Given the investment horizon of 90 days Acrivon Therapeutics, is expected to generate 859.74 times less return on investment than Protagenic Therapeutics. But when comparing it to its historical volatility, Acrivon Therapeutics, Common is 30.17 times less risky than Protagenic Therapeutics. It trades about 0.01 of its potential returns per unit of risk. Protagenic Therapeutics is currently generating about 0.19 of returns per unit of risk over similar time horizon. If you would invest  1.40  in Protagenic Therapeutics on August 31, 2024 and sell it today you would lose (0.45) from holding Protagenic Therapeutics or give up 32.14% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Very Weak
Accuracy	39.57%
Values	Daily Returns

Acrivon Therapeutics, Common  vs.  Protagenic Therapeutics

Acrivon Therapeutics,

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Acrivon Therapeutics, Common has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest unsteady performance, the Stock's basic indicators remain stable and the latest fuss on Wall Street may also be a sign of long-term gains for the venture sophisticated investors.

Protagenic Therapeutics

Risk-Adjusted Performance

17 of 100

Solid

Compared to the overall equity markets, risk-adjusted returns on investments in Protagenic Therapeutics are ranked lower than 17 (%) of all global equities and portfolios over the last 90 days. In spite of fairly abnormal basic indicators, Protagenic Therapeutics showed solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Acrivon Therapeutics, and Protagenic Therapeutics

The main advantage of trading using opposite Acrivon Therapeutics, and Protagenic Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Acrivon Therapeutics, position performs unexpectedly, Protagenic Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Protagenic Therapeutics will offset losses from the drop in Protagenic Therapeutics' long position.

The idea behind Acrivon Therapeutics, Common and Protagenic Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.